VAY-736 combines effectively with ibrutinib in vivo.

Slides:

Advertisements

Similar presentations

Mary Armanios, Jonathan K. Alder, Erin M

Advertisements

Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact.

Combination therapy for adult T-cell leukemia–xenografted mice: flavopiridol and anti-CD25 monoclonal antibody by Meili Zhang, Zhuo Zhang, Carolyn K. Goldman,

William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D

Emma L. Cambridge, Zoe McIntyre, Simon Clare, Mark J

The ETS factor TEL2 is a hematopoietic oncoprotein

Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad by Anna Frenzel, Verena Labi, Waldemar Chmelewskij, Christian Ploner, Stephan.

Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate.

Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo by Farideh Miraki-Moud, Essam.

by David Traver, Alissa Winzeler, Howard M. Stern, Elizabeth A

Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers by Andrea.

Splenic proliferative lymphoid nodules distinct from germinal centers are sites of autoantigen stimulation in immune thrombocytopenia by Capucine Daridon,

CCR2 is required for CD8-induced graft-versus-host disease

Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.

William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D

Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging by Matthias Edinger, Yu-An Cao, Michael R. Verneris,

Runx1 deficiency predisposes mice to T-lymphoblastic lymphoma

IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation by Christoph Bucher, Lisa Koch, Christine.

Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy by Mark P. Chao, Chad Tang, Russell K. Pachynski,

Jacob Andrade, Shundi Ge, Goar Symbatyan, Michael S. Rosol, Arthur J

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia by Donya Moradi Manesh, Jad El-Hoss, Kathryn.

C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma by Aldo M. Roccaro, Antonio.

by Signe Hässler, Chris Ramsey, Mikael C

Fanconi anemia type C and p53 cooperate in apoptosis and tumorigenesis

The Requirement for Cyclin D Function in Tumor Maintenance

by Hyung-Gyoon Kim, Kyoko Kojima, C. Scott Swindle, Claudiu V

Lack of the adhesion molecules P-selectin and intercellular adhesion molecule-1 accelerate the development of BCR/ABL-induced chronic myeloid leukemia-like.

by Feng Guo, Debra Weih, Elke Meier, and Falk Weih

Blocking LFA-1 Activation with Lovastatin Prevents Graft-versus-Host Disease in Mouse Bone Marrow Transplantation Yang Wang, Dan Li, Dan Jones, Roland.

Attenuated MDSC-suppressive activity and metastasis development in IDO-deficient mice is rescued by IL-6. Attenuated MDSC-suppressive activity and metastasis.

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

by Atsuhiko Hasegawa, Huining Liu, Binhua Ling, Juan T

FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant.

Jacob Andrade, Shundi Ge, Goar Symbatyan, Michael S. Rosol, Arthur J

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia by Zachary A. Hing, Rose Mantel,

Fig. 8. In vivo suppression of MM by CMLD

Volume 25, Issue 3, Pages (March 2017)

ALT-803 administration increases peripheral blood cell counts of lymphocyte subsets in cynomolgus monkeys. ALT-803 administration increases peripheral.

Functional interaction of Eμ-Tcl1 tumor cells with FDC networks.

Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies by Yi Tian Png, Natasha Vinanica, Takahiro.

Volume 1, Issue 4, Pages (May 2002)

Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice by Rikke Stagaard, Carsten Dan Ley, Kasper Almholt,

Anti–BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib by Emily M. McWilliams, Christopher.

by Kamira Maharaj, John J

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Volume 24, Issue 9, Pages (September 2016)

STAT1 acts as a tumor promoter for leukemia development

Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines by Yanyan Zhang, Liang He, Dorothée.

Hematological phenotypes of hema6 mice.

Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras by S. Haihua Chu, Evelyn J. Song,

by Geling Li, Emily Waite, and Julie Wolfson

A rapid, spontaneous, and fully penetrant model of cytogenetically normal AML utilizing Flt3ITD and Dnmt3a haploinsufficiency. A rapid, spontaneous, and.

Blimp-1 Transcription Factor Is Required for the Differentiation of Effector CD8+ T Cells and Memory Responses Axel Kallies, Annie Xin, Gabrielle T.

CXCR5 expression accelerates Eμ-Tcl1 leukemogenesis and is indispensable for tumor cell recruitment to lymphoid B-cell follicles. CXCR5 expression accelerates.

Lack of correlation between an assay used to determine early marrow allograft rejection and long-term chimerism after murine allogeneic bone marrow transplantation:

Serial vaccination with 32Dp210-derived whole cell vaccines in non-tumor-bearing mice stimulates robust antileukemic cytolytic activity. Serial vaccination.

by Gabriela M. Webb, Shengbin Li, Gwantwa Mwakalundwa, Joy M

BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia by Yo-Ting Tsai, Aparna Lakshmanan, Amy Lehman,

Instigating, noninstigating, and responding human tumor specimens.

Intratumoral platelet aggregate formation in a murine preclinical glioma model depends on podoplanin expression on tumor cells by Barbara Costa, Tanja.

TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 has antileukemia activity in an in vivo primary AML xenograft.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

Hmga2 expression augments BM cells and HSCs with enhancing extramedullary hematopoiesis in JAK2V617F-induced MPN. (A) The total nuclear cell numbers from.

ESKM is superior to ESK1 in vivo, and is effective against multiple tumor models. ESKM is superior to ESK1 in vivo, and is effective against multiple tumor.

Crebbp deficiency accelerates B-cell lymphoma development in mice.

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

Constitutive expression of JAK3M511I and HOXA9 leads to development of both AML and T-ALL in vivo. Constitutive expression of JAK3M511I and HOXA9 leads.

Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,

ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared with ibrutinib. ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared.

Reduced pathological damage in lungs and spleens of guinea pigs infected with H37Rv upon AZD0530 treatment. Reduced pathological damage in lungs and spleens.

Presentation transcript:

VAY-736 combines effectively with ibrutinib in vivo. VAY-736 combines effectively with ibrutinib in vivo. Tumor-derived splenocytes from disease-burdened Eμ-TCL1 mice were engrafted into SCID mice. (A) Kaplan-Meier survival plot receiving weekly VAY-736 (10 mg/kg) retro-orbital injections, vehicle control injections, ibrutinib drinking water, or combination VAY-736 + ibrutinib, for up to 6 injections of VAY-736 or vehicle, and continuous ibrutinib drinking water provided through study. Leukemic death was confirmed upon death by fluorescence-activated cell sorting analysis of blood, spleen, and bone marrow CD5+ CD19+ percentage of lymphocytes (VAY-736 + ibrutinib vs ibrutinib, P < .0001; VAY-736 + ibrutinib vs VAY-736, P = .06; n = 14 per group). Adjustments for multiple comparisons for the log-rank test were used for data analysis. *P < .05 and **P < .01. (B) After 6 weeks, 2 animals per group were euthanized and samples sent for histopathology analysis. Splenic white pulp expanded by leukemia cells is visible as white foci in the enlarged spleens. Splenic white pulp areas (arrows) and red pulp (arrow heads) are infiltrated and expanded by leukemia cells in all specimens. Top row: photomicrographs at low-power magnification to show level of infiltration (magnification ×20; hematoxylin and eosin stain). Middle row: high-power magnification to show cellular detail (magnification ×60; hematoxylin and eosin stain). Mitotic figures are indicated with an asterisk. Bottom row: gross anatomy images of spleens. White blood cell (WBC) counts from blood smears (C) and CD5+ CD19+ percent circulating lymphocytes (D) were observed weekly for leukemia progression. (E-F) At death, spleen and bone marrow were analyzed by fluorescence-activated cell sorting for percent lymphocytes CD5+ CD19+. (G) Kaplan-Meier survival plot of a repeated experiment described in panel A except with engraftment into NOTAM mice lacking functional FcRγ (VAY-736 + ibrutinib vs ibrutinib, P = .4921; VAY-736 vs vehicle, P = .7453; n = 7 to 8 per group). NS, not significant. Emily M. McWilliams et al. Blood Adv 2019;3:447-460 © 2019 by The American Society of Hematology